Physician profile
Erden Goljo
NPI 1770931313
$63,699.68
in general payments reported to CMS, 2019-2025
16 companies · $19K in 2025
The $19K reported for 2025 was more than what 88% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,894 · 2022: $17K · 2023: $15K · 2024: $9,129 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $12K · Food and Beverage: $11K · Consulting Fee: $9,669 · Travel and Lodging: $9,272 · Education: $440 · Entertainment: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $12,375.00 |
| Food and Beverage | $10,596.40 |
| Consulting Fee | $9,668.84 |
| Travel and Lodging | $9,271.76 |
| Education | $439.68 |
| Entertainment | $269.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22,536.49 | 2021-2025 | Tacticath Ablation Catheter, Sensor Enabled, Aveir, Tendril |
| Biotronik INC. | $15,981.62 | 2021-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Medtronic, INC. | $14,361.09 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Boston Scientific Corporation | $9,034.55 | 2022-2025 | Farapulse, Rhythmia Mapping System |
| Biosense Webster, INC. | $513.16 | 2024-2025 | Carto 3 |
| Ebr Systems, INC. | $325.25 | 2025 | |
| Stereotaxis INC | $269.50 | 2024-2025 | Genesis |
| Astrazeneca Pharmaceuticals Lp | $156.76 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $123.17 | 2025 | Optimizer |
| Sanofi-Aventis U.S. LLC | $115.99 | 2022 | |
| Amgen INC. | $85.58 | 2021-2022 | |
| Cardiva Medical, INC. | $67.20 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Pfizer INC. | $44.07 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.02 | 2021 | |
| Edwards Lifesciences Corporation | $20.75 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $20.48 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erden Goljo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.